Expertise in
6
conditions

Gabriella Galffy

70 Munkácsy Mihály Street, 
Toeroekbalint, PE, HU 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
6
conditions
70 Munkácsy Mihály Street, 
Toeroekbalint, PE, HU 

Overview

Gabriella Galffy practices practicing medicine in Toeroekbalint, Hungary.

Ms. Galffy is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Allergic Rhinitis, Lung Cancer, Small Cell Lung Cancer (SCLC), and Chronic Obstructive Pulmonary Disease (COPD).

She is actively involved in clinical research, co-authoring 89 peer reviewed articles and participating in 5 clinical trials.

Gender

Female

Locations

70 Munkácsy Mihály Street, Toeroekbalint, PE 2045, Hungary
Other Locations
58 Tűzoltó Street, Budapest, BU 1085, Hungary

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: APL-101
Study Phase: Phase 2
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Patients With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Patients With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drugs: Bevacizumab, HD204, Carboplatin, Paclitaxel
Study Phase: Phase 3
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: August 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Enrollment Status: Completed
Publish Date: June 03, 2024
View 4 Less Clinical Trials

89 Total Publications

Human Leukocyte Antigen-DR Expression on Monocytes Is a Useful Predictor in a Systemic Inflammation Response-Based Prognostic Model in Advanced Non-Small Cell Lung Cancer.
Human Leukocyte Antigen-DR Expression on Monocytes Is a Useful Predictor in a Systemic Inflammation Response-Based Prognostic Model in Advanced Non-Small Cell Lung Cancer.
Journal: International journal of molecular sciences
Published: August 05, 2025

Frequently Asked Questions about Gabriella Galffy

Is Gabriella Galffy a top-rated expert for Allergic Rhinitis?

MediFind is an objective health platform that identifies experts based on real-world data. Gabriella Galffy is classified as an Distinguished expert for Allergic Rhinitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Gabriella Galffy participate in research or clinical trials?

Yes. Gabriella Galffy has published 89 articles and abstracts on conditions like Allergic Rhinitis. You can view a list of Gabriella Galffy's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Galffy's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile